We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan.
- Authors
Zhao, Ming; DiPeri, Timothy P.; Raso, Maria Gabriela; Zheng, Xiaofeng; Rizvi, Yasmeen Qamar; Evans, Kurt W.; Yang, Fei; Akcakanat, Argun; Roberto Estecio, Marco; Tripathy, Debu; Dumbrava, Ecaterina E.; Damodaran, Senthil; Meric-Bernstam, Funda
- Abstract
TROP2 antibody drug conjugates (ADCs) are under active development. We seek to determine whether we can enhance activity of TROP2 ADCs by increasing TROP2 expression. In metaplastic breast cancers (MpBC), there is limited expression of TROP2, and downregulating transcription factor ZEB1 upregulates E-cad and TROP2, thus sensitizing cancers to TROP2 ADC sacituzumab govitecan (SG). Demethylating agent decitabine decreases DNA methyltransferase expression and TROP2 promoter methylation and subsequently increases TROP2 expression. Decitabine treatment as well as overexpression of TROP2 significantly enhance SG antitumor activity. Decitabine also increases SLFN11, a biomarker of topoisomerase 1 inhibitor (TOP1) sensitivity and is synergistic with SG which has a TOP1 payload, in TROP2-expressing SLFN11-low BC cells. In conclusion, TROP2 and SLFN11 expression can be epigenetically modulated and the combination of demethylating agent decitabine with TROP2 ADCs may represent a novel therapeutic approach for tumors with low TROP2 or SLFN11 expression.
- Subjects
DECITABINE; TREATMENT effectiveness; DNA topoisomerase I; TRANSCRIPTION factors; IMMUNOGLOBULINS; ANTINEOPLASTIC agents
- Publication
NPJ Breast Cancer, 2023, Vol 9, Issue 1, p1
- ISSN
2374-4677
- Publication type
Article
- DOI
10.1038/s41523-023-00573-8